• Je něco špatně v tomto záznamu ?

Microbiome and Metabolome Profiles Associated With Different Types of Short Bowel Syndrome: Implications for Treatment

E. Budinska, J. Gojda, M. Heczkova, M. Bratova, H. Dankova, P. Wohl, H. Bastova, V. Lanska, M. Kostovcik, M. Dastych, M. Senkyrik, J. Krizova, M. Mraz, J. Hradecky, J. Hajslova, M. Lenicek, K. Podzimkova, K. Chalupsky, R. Sedlacek, M. Cahova

. 2020 ; 44 (1) : 105-118. [pub] 20190429

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20016615

Grantová podpora
NV15-28745A MZ0 CEP - Centrální evidence projektů

BACKGROUND: The gut microbiome and metabolome may significantly influence clinical outcomes in patients with short bowel syndrome (SBS). The study aimed to describe specific metagenomic/metabolomics profiles of different SBS types and to identify possible therapeutic targets. METHODS: Fecal microbiome (FM), volatile organic compounds (VOCs), and bile acid (BA) spectrum were analyzed in parenteral nutrition (PN)-dependent SBS I, SBS II, and PN-independent (non-PN) SBS patients. RESULTS: FM in SBS I, SBS II, and non-PN SBS shared characteristic features (depletion of beneficial anaerobes, high abundance of Lactobacilaceae and Enterobacteriaceae). SBS I patients were characterized by the abundance of oxygen-tolerant microrganisms and depletion of strict anaerobes. Non-PN SBS subjects showed markers of partial FM normalization. FM dysbiosis was translated into VOC and BA profiles characteristic for each SBS cohort. A typical signature of all SBS patients comprised high saturated aldehydes and medium-chain fatty acids and reduced short-chain fatty acid (SCFA) content. Particularly, SBS I and II exhibited low protein metabolism intermediate (indole, p-cresol) content despite the hypothetical presence of relevant metabolism pathways. Distinctive non-PN SBS marker was high phenol content. SBS patients' BA fecal spectrum was enriched by chenodeoxycholic and deoxycholic acids and depleted of lithocholic acid. CONCLUSIONS: Environmental conditions in SBS gut significantly affect FM composition and metabolic activity. The common feature of diverse SBS subjects is the altered VOC/BA profile and the lack of important products of microbial metabolism. Strategies oriented on the microbiome/metabolome reconstitution and targeted delivery of key compounds may represent a promising therapeutic strategy in SBS patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20016615
003      
CZ-PrNML
005      
20240627144508.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jpen.1595 $2 doi
035    __
$a (Pubmed)31032975
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Budinská, Eva $7 xx0142844 $u RECETOX, Faculty of Science Masaryk University, Brno, Czech Republic
245    10
$a Microbiome and Metabolome Profiles Associated With Different Types of Short Bowel Syndrome: Implications for Treatment / $c E. Budinska, J. Gojda, M. Heczkova, M. Bratova, H. Dankova, P. Wohl, H. Bastova, V. Lanska, M. Kostovcik, M. Dastych, M. Senkyrik, J. Krizova, M. Mraz, J. Hradecky, J. Hajslova, M. Lenicek, K. Podzimkova, K. Chalupsky, R. Sedlacek, M. Cahova
520    9_
$a BACKGROUND: The gut microbiome and metabolome may significantly influence clinical outcomes in patients with short bowel syndrome (SBS). The study aimed to describe specific metagenomic/metabolomics profiles of different SBS types and to identify possible therapeutic targets. METHODS: Fecal microbiome (FM), volatile organic compounds (VOCs), and bile acid (BA) spectrum were analyzed in parenteral nutrition (PN)-dependent SBS I, SBS II, and PN-independent (non-PN) SBS patients. RESULTS: FM in SBS I, SBS II, and non-PN SBS shared characteristic features (depletion of beneficial anaerobes, high abundance of Lactobacilaceae and Enterobacteriaceae). SBS I patients were characterized by the abundance of oxygen-tolerant microrganisms and depletion of strict anaerobes. Non-PN SBS subjects showed markers of partial FM normalization. FM dysbiosis was translated into VOC and BA profiles characteristic for each SBS cohort. A typical signature of all SBS patients comprised high saturated aldehydes and medium-chain fatty acids and reduced short-chain fatty acid (SCFA) content. Particularly, SBS I and II exhibited low protein metabolism intermediate (indole, p-cresol) content despite the hypothetical presence of relevant metabolism pathways. Distinctive non-PN SBS marker was high phenol content. SBS patients' BA fecal spectrum was enriched by chenodeoxycholic and deoxycholic acids and depleted of lithocholic acid. CONCLUSIONS: Environmental conditions in SBS gut significantly affect FM composition and metabolic activity. The common feature of diverse SBS subjects is the altered VOC/BA profile and the lack of important products of microbial metabolism. Strategies oriented on the microbiome/metabolome reconstitution and targeted delivery of key compounds may represent a promising therapeutic strategy in SBS patients.
650    _2
$a Bacteria $x klasifikace $7 D001419
650    _2
$a žlučové kyseliny a soli $x analýza $7 D001647
650    _2
$a dysbióza $7 D064806
650    _2
$a feces $x mikrobiologie $7 D005243
650    12
$a střevní mikroflóra $7 D000069196
650    _2
$a lidé $7 D006801
650    12
$a metabolom $7 D055442
650    _2
$a parenterální výživa $7 D010288
650    _2
$a syndrom krátkého střeva $x mikrobiologie $7 D012778
650    _2
$a těkavé organické sloučeniny $x analýza $7 D055549
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gojda, Jan $d 1983- $7 xx0212530 $u 2nd Department of Internal Medicine, Kralovske Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Heczková, Marie $7 xx0102189 $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Brátová, Miriam $7 xx0248520 $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Daňková, Helena $7 xx0239615 $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Wohl, Petr $d 1970- $7 xx0054426 $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Bastova, Hana $7 _AN083646 $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Lánská, Věra $7 xx0062305 $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kostovcik, Martin $u BIOCEV, Institute of Microbiology, AS CR, Vestec, Czech Republic
700    1_
$a Dastych, Milan $u Department of Gastroenterology and Internal Medicine, University Hospital Brno, Brno, Czech Republic
700    1_
$a Šenkyřík, Michal $7 xx0106448 $u Department of Gastroenterology and Internal Medicine, University Hospital Brno, Brno, Czech Republic
700    1_
$a Křížová, Jarmila $7 xx0017659 $u 3rd Department of Medicine, Department of Endocrinology and Metabolism, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mráz, Miloš $7 xx0119173 $u 2nd Department of Internal Medicine, Kralovske Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hradecky, Jaromir $u University of Chemistry and Technology, Prague, Czech Republic $u Faculty of Forestry and Wood Sciences, Czech University of Life Sciences, Prague, Czech Republic
700    1_
$a Hajšlová, Jana $d 1952- $7 uzp2006333635 $u University of Chemistry and Technology, Prague, Czech Republic
700    1_
$a Leníček, Martin $7 xx0097551 $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Podzimkova, Kateřina $u Czech Centre for Phenogenomics, Vestec, Czech Republic $u Laboratory of Transgenic Diseases, Institute of Molecular Genetics CAS, Prague, Czech Republic
700    1_
$a Chalupský, Karel $u Czech Centre for Phenogenomics, Vestec, Czech Republic $u Laboratory of Transgenic Diseases, Institute of Molecular Genetics CAS, Prague, Czech Republic
700    1_
$a Sedláček, Radislav, $d 1965- $7 xx0140532 $u Czech Centre for Phenogenomics, Vestec, Czech Republic $u Laboratory of Transgenic Diseases, Institute of Molecular Genetics CAS, Prague, Czech Republic
700    1_
$a Cahová, Monika $7 xx0070633 $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
773    0_
$t JPEN. Journal of parenteral and enteral nutrition $x 1941-2444 $g Roč. 44, č. 1 (2020), s. 105-118 $w MED00002877
910    __
$a ABA008 $y p $z 0 $b sig $c sign
990    __
$a 20201023113228 $b ABA008
991    __
$a 20240627144502 $b ABA008
999    __
$a ok $b bmc $g 1575325 $s 1106791
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 44 $c 1 $d 105-118 $x MED00002877 $i 1941-2444 $m JPEN. Journal of parenteral and enteral nutrition $e 20190429 $n JPEN J Parenter Enteral Nutr
GRA    __
$a NV15-28745A $p MZ0
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace